Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100139 | 0.86 | GAA (0.49) | GAAMAPK1TSHRCA12CA1 | |
| SCHEMBL3109923 | 0.83 | GAA (0.50) | GAAMAPK1TSHRCA12CA1 | |
| SCHEMBL168008 | 0.81 | MAPT (0.40) | GAAMAPK1TSHRCA12CA1 | |
| SCHEMBL16863717 | 0.80 | GAA (0.50) | GAAMAPK1TSHRCA12CA1 | |
| SCHEMBL3094886 | 0.79 | GAA (0.43) | GAAMAPK1TSHRCA12CA1 | |
| SCHEMBL20723582 | 0.79 | KDM4E (0.48) | GAAMAPK1TSHRALDH1A1MAPT | |
| SCHEMBL168837 | 0.79 | GAA (0.71) | GAAMAPK1TSHRALDH1A1MAPT | |
| SCHEMBL8630776 | 0.79 | GAA (0.49) | GAAMAPK1TSHRCA12CA1 | |
| SCHEMBL29359967 | 0.79 | GAA (0.49) | GAAMAPK1TSHRCA12CA1 | |
| SCHEMBL23413574 | 0.78 | GAA (0.54) | GAATSHRALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555078-B1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| CN-111356695-B | Novel tricyclic compounds | 北京加科思新药研发有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-14 | — | — | US | disclosed |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-14 | — | — | US | disclosed |
| CN-111356695-A | Novel tricyclic compounds | 北京加科思图新药研发有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-20200062781-A1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| US-20200062781-A1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| EP-3555078-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109643-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062781-A1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | GAA 1856/4885MAPK1 2708/4885TSHR 3801/4885 |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | NFE2L2, KEAP1, NQO1 | GAA 1856/4885MAPK1 2708/4885TSHR 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.